All In Biotech

Drug Trial Radar · NCT06136741

A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis

A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis (REZOLVE-AD)

Last checked: Nov 20, 2026Latest source record: Aug 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 396 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

396

Planned (sponsor's estimate)

Start

Nov 15, 2023

Primary completion

May 6, 2025

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Nektar TherapeuticsIndustry
Sponsor type
Industry
First posted
Nov 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an interventional, randomized, parallel group, treatment, Phase IIb, double blind, 4-arm study to assess the effect of pegylated-recombinant-human interleukin-2 (rezpegaldesleukin) in adult participants with moderate to severe atopic dermatitis. The estimated duration is 15-35 days for screening, an Induction Period of 16 weeks, a Maintenance Period from Week 16-Week 52, and a Posttreatment Follow-Up Period for an additional year up to approximately Week 104 for all patients. Patients with a response at Week 16 (end of induction therapy) will be re-randomized for the maintenance therapy period.

Conditions

  • Moderate to Severe Atopic Dermatitis

Interventions

  • RezpegaldesleukinDrug

    Pharmaceutical form: Injection solution Route of administration: subcutaneous

  • PlaceboDrug

    Pharmaceutical form: Injection solution Route of administration: subcutaneous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean percent change in the Eczema Area and Severity Index (EASI) from baseline at Week 16Time frame: Week 0 and Week 16

Locations

107 sites in 10 countries. Site status is shown where the registry gives one.

  • Nektar Investigative Site

    Bryant, Arkansas

  • Nektar Investigative Site

    Fountain Valley, California

  • Nektar Investigative Site

    Los Angeles, California

  • Nektar Investigative Site

    Los Angeles, California

  • Nektar Investigative Site

    Los Angeles, California

  • Nektar Investigative Site

    Santa Monica, California

  • Nektar Investigative Site

    Hialeah, Florida

  • Nektar Investigative Site

    Hollywood, Florida

  • Nektar Investigative Site

    Miami, Florida

  • Nektar Investigative Site

    Miami Lakes, Florida

  • Nektar Investigative Site

    St. Petersburg, Florida

  • Nektar Investigative Site

    Tampa, Florida

  • Nektar Investigative Site

    Marietta, Georgia

  • Nektar Investigative Site

    Clarksville, Indiana

  • Nektar Investigative Site

    Indianapolis, Indiana

  • Nektar Investigative Site

    Louisville, Kentucky

  • Nektar Investigative Site

    Flint, Michigan

  • Nektar Investigative Site

    Troy, Michigan

  • Nektar Investigative Site

    Las Vegas, Nevada

  • Nektar Investigative Site

    New York, New York

  • Nektar Investigative Site

    Fairborn, Ohio

  • Nektar Investigative Site

    Mayfield Heights, Ohio

  • Nektar Investigative Site

    Murfreesboro, Tennessee

  • Nektar Investigative Site

    Bellaire, Texas

  • Nektar Investigative Site

    Cypress, Texas

  • Nektar Investigative Site

    Frisco, Texas

  • Nektar Investigative Site

    Spokane, Washington

  • Nektar Investigative Site

    Spokane, Washington

  • Nektar Investigative Site

    Darlinghurst, New South Wales, Australia

  • Nektar Investigative Site

    Kogarah, New South Wales, Australia

  • Nektar Investigative Site

    Westmead, New South Wales, Australia

  • Nektar Investigative Site

    Woolloongabba, Queensland, Australia

  • Nektar Investigative Site

    Campbelltown, South Australia, Australia

  • Nektar Investigative Site

    East Melbourne, Victoria, Australia

  • Nektar Investigative Site

    Melbourne, Victoria, Australia

  • Nektar Investigative Site

    Lovech, Bulgaria

  • Nektar Investigative Site

    Pleven, Bulgaria

  • Nektar Investigative Site

    Sofia, Bulgaria

  • Nektar Investigative Site

    Sofia, Bulgaria

  • Nektar Investigative Site

    Sevlievo, Gabrovo, Bulgaria

Showing 40 of 107 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.